Phase II study of tivantinib (ARQ 197) in patients with metastatic triple-negative breast cancer

Background MET expression and activation appear to be important for initiation and progression of triple-negative breast cancer. Tivantinib (ARQ 197) is an orally administered agent that targets MET, although recent preclinical data suggests the agent may have mechanisms of action that are independe...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Invest New Drugs
Main Authors: Tolaney, Sara M., Tan, Sally, Guo, Hao, Barry, William, Van Allen, Eliezer, Wagle, Nikhil, Brock, Jane, Larrabee, Katherine, Paweletz, Cloud, Ivanova, Elena, Janne, Pasi, Overmoyer, Beth, Wright, John J., Shapiro, Geoffrey I., Winer, Eric P., Krop, Ian E.
Formato: Artigo
Idioma:Inglês
Publicado em: Springer US 2015
Assuntos:
Phase II Studies
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC4608248/
https://ncbi.nlm.nih.gov/pubmed/26123926
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s10637-015-0269-8
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados